UBE2Q1 and ovarian serous adenocarcinoma: An integrated gene expression analysis, both using DEGs and WGCNA, identified UBE2Q1, a yet less explored E2 ubiquitin-conjugating enzyme, as a potential prognostic marker associated with poor relapse-free survival and response outcome to platin/taxane treatment of patients with high grade serous ovarian cancer.